These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 24263002)

  • 1. Drug-drug interaction of the anti-TFPI aptamer BAX499 and factor VIII: studies of spatial dynamics of fibrin clot formation in hemophilia A.
    Parunov LA; Soshitova NP; Fadeeva OA; Balandina AN; Kopylov KG; Kumskova MA; Gilbert JC; Schaub RG; McGinness KE; Ataullakhanov FI; Panteleev MA
    Thromb Res; 2014 Jan; 133(1):112-9. PubMed ID: 24263002
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improvement of spatial fibrin formation by the anti-TFPI aptamer BAX499: changing clot size by targeting extrinsic pathway initiation.
    Parunov LA; Fadeeva OA; Balandina AN; Soshitova NP; Kopylov KG; Kumskova MA; Gilbert JC; Schaub RG; McGinness KE; Ataullakhanov FI; Panteleev MA
    J Thromb Haemost; 2011 Sep; 9(9):1825-34. PubMed ID: 21696535
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Studies on the mechanism of action of the aptamer BAX499, an inhibitor of tissue factor pathway inhibitor.
    Chang JY; Chantrathammachart P; Monroe DM; Key NS
    Thromb Res; 2012 Sep; 130(3):e151-7. PubMed ID: 22658294
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of BAX499 aptamer on tissue factor pathway inhibitor function and thrombin generation in models of hemophilia.
    Gissel M; Orfeo T; Foley JH; Butenas S
    Thromb Res; 2012 Dec; 130(6):948-55. PubMed ID: 22951415
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aptamer ARC19499 mediates a procoagulant hemostatic effect by inhibiting tissue factor pathway inhibitor.
    Waters EK; Genga RM; Schwartz MC; Nelson JA; Schaub RG; Olson KA; Kurz JC; McGinness KE
    Blood; 2011 May; 117(20):5514-22. PubMed ID: 21389323
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of tissue factor pathway inhibitor by the aptamer BAX499 improves clotting of hemophilic blood and plasma.
    Gorczyca ME; Nair SC; Jilma B; Priya S; Male C; Reitter S; Knoebl P; Gilbert JC; Schaub RG; Dockal M; McGinness KE; Pabinger I; Srivastava A
    J Thromb Haemost; 2012 Aug; 10(8):1581-90. PubMed ID: 22632032
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factor XIII cotreatment with hemostatic agents in hemophilia A increases fibrin α-chain crosslinking.
    Beckman JD; Holle LA; Wolberg AS
    J Thromb Haemost; 2018 Jan; 16(1):131-141. PubMed ID: 29080382
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hemostatic effect of a monoclonal antibody mAb 2021 blocking the interaction between FXa and TFPI in a rabbit hemophilia model.
    Hilden I; Lauritzen B; Sørensen BB; Clausen JT; Jespersgaard C; Krogh BO; Bowler AN; Breinholt J; Gruhler A; Svensson LA; Petersen HH; Petersen LC; Balling KW; Hansen L; Hermit MB; Egebjerg T; Friederichsen B; Ezban M; Bjørn SE
    Blood; 2012 Jun; 119(24):5871-8. PubMed ID: 22563084
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasmatic tissue factor pathway inhibitor is a major determinant of clotting in factor VIII inhibited plasma or blood.
    Knappe S; Gorczyca ME; Jilma B; Derhaschnig U; Hartmann R; Palige M; Scheiflinger F; Dockal M
    Thromb Haemost; 2013 Mar; 109(3):450-7. PubMed ID: 23348798
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hemostatic properties of a TFPI antibody.
    Petersen LC
    Thromb Res; 2012 May; 129 Suppl 2():S44-5. PubMed ID: 22405586
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of factor VIII on tissue factor-initiated spatial clot growth.
    Ovanesov MV; Lopatina EG; Saenko EL; Ananyeva NM; Ul'yanova LI; Plyushch OP; Butilin AA; Ataullakhanov FI
    Thromb Haemost; 2003 Feb; 89(2):235-42. PubMed ID: 12574801
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elevated factor VIII enhances thrombin generation in the presence of factor VIII-deficiency, factor XI-deficiency or fondaparinux.
    Szlam F; Sreeram G; Solomon C; Levy JH; Molinaro RJ; Tanaka KA
    Thromb Res; 2011 Feb; 127(2):135-40. PubMed ID: 21144556
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Measurement of global haemostasis in severe haemophilia A following factor VIII infusion.
    Lewis SJ; Stephens E; Florou G; Macartney NJ; Hathaway LS; Knipping J; Collins PW
    Br J Haematol; 2007 Sep; 138(6):775-82. PubMed ID: 17672884
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting TFPI for hemophilia treatment.
    Peterson JA; Maroney SA; Mast AE
    Thromb Res; 2016 May; 141 Suppl 2(Suppl 2):S28-30. PubMed ID: 27207418
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improvement of fibrin clot structure after factor VIII injection in haemophilia A patients treated on demand.
    Antovic A; Mikovic D; Elezovic I; Zabczyk M; Hutenby K; Antovic JP
    Thromb Haemost; 2014 Apr; 111(4):656-61. PubMed ID: 24258360
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of extrinsic pathway inhibitor shortens the coagulation time of normal plasma and of hemophilia plasma.
    Nordfang O; Valentin S; Beck TC; Hedner U
    Thromb Haemost; 1991 Oct; 66(4):464-7. PubMed ID: 1796397
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stabilization of fibrin clots by activated prothrombin complex concentrate and tranexamic acid in FVIII inhibitor plasma.
    Dai L; Bevan D; Rangarajan S; Sørensen B; Mitchell M
    Haemophilia; 2011 Sep; 17(5):e944-8. PubMed ID: 21371192
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent advances in the development of coagulation factors and procoagulants for the treatment of hemophilia.
    Schaub RG
    Biochem Pharmacol; 2011 Jul; 82(2):91-8. PubMed ID: 21453683
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved coagulation in bleeding disorders by Non-Anticoagulant Sulfated Polysaccharides (NASP).
    Liu T; Scallan CD; Broze GJ; Patarroyo-White S; Pierce GF; Johnson KW
    Thromb Haemost; 2006 Jan; 95(1):68-76. PubMed ID: 16543964
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of Tissue Factor Pathway Inhibitor (TFPI) as a Treatment for Haemophilia: Rationale with Focus on Concizumab.
    Chowdary P
    Drugs; 2018 Jun; 78(9):881-890. PubMed ID: 29845491
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.